SynsoryBio

We are a drug discovery company developing a new generation of therapeutics that embrace the complexity of disease. Currently available approaches for creating drugs work on the principle of finding one drug-one protein 'magic bullets'. However, diseases such as cancer and autoimmunity are often the result of several dysregulated proteins across many distinct biological pathways. We are building a computational-experimental platform to design therapeutics that can target several disease-causing

shared product terms: drug, generation, therapeutic, disease; shared product theme: health and clinical care; same category: Healthcare; shared affiliation: Y Combinator

SFA Therapeutics is creating therapeutically-tailored oral drugs that regulate the immune system; with a focus on autoimmune diseases and cancers that originate from chronic inflammation. There are over 300 million patients who suffer from autoimmune diseases. Our treatment is designed to block the root cause of many of these chronic inflammatory diseases, with safe oral drugs. We have strong clinical data from a phase 1b clinical trial in psoriasis, and human data in pancreatic cancer, uveitis

shared product terms: therapeutic, creat, drug, autoimmune; shared product theme: health and clinical care; same category: Healthcare; shared affiliation: Y Combinator

We use AI and high-throughput mouse studies to discover therapeutics that modify neural activity in the brain. The initial focus is on epilepsies associated with autism and Parkinson’s disease with the potential to expand to any neurological disorder underlined by a dysfunction in neural activity. Our R&D is guided by AI models trained on high-density multimodal mouse data generated in-house. We are 3 Oxford-trained neuroscientists supported by an experienced SAB from Harvard, Science Corp (ex-N

shared extracted concept terms: therapeutic; shared product terms: therapeutic, disease, potential, expand; shared product theme: health and clinical care; shared affiliation: Y Combinator

The future of mRNA therapeutics is hampered by manufacturing challenges and unless solved, its exciting potential may never be realised. Sensible enables the next generation of mRNA medicines by turning living cells into factories producing abundant, highly stable and non-immunogenic mRNA in a scalable and cost-effective way.

shared product terms: therapeutic, potential, next, generation; shared product theme: health and clinical care; same category: Healthcare; shared affiliation: Y Combinator

At Studdy, our mission is to unlock the full potential of the next generation by providing a personalized AI tutor for every student. Studdy Buddy is a multilingual tutor that uses AI, as well as advanced speech, text, and image recognition technology to supercharge students' ability to learn new subjects. We believe that making self-learning as easy as possible for as many students as possible (no matter their cultural, social, or educational background) is the key to unlocking the full potenti

shared extracted concepts: next generation; shared product terms: potential, next, generation, many; shared affiliation: Y Combinator

Sixfold is focused on the commercialisation of its patented drug delivery systems for RNA therapeutics such as siRNAs for gene silencing and mRNAs for gene expression.

shared extracted concept terms: therapeutic; shared product terms: drug, therapeutic, such; shared product theme: health and clinical care; same category: Healthcare; shared affiliation: Y Combinator